



August 08, 2022

To

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400 001  
Tel: 022 - 2272 1233 /4  
Fax: 022 - 22721919

Ref: Aragen Life Sciences Private Limited

Scrip Code: 973783

ISIN: INE483I07010

**Sub: Publication of Extract of Financial Results in an English national daily newspaper**

In compliance with Regulation 52 (8) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, the Company has, on Friday, 05<sup>th</sup> August, 2022, published in The Economic Times, an English national daily newspaper, the extracts of the Revised Financial Results for the quarter and the year ended 31<sup>st</sup> March, 2022 and the Financial Results for the quarter ended 30<sup>th</sup> June, 2022, which were approved by its Board of Directors and disseminated on Wednesday, the 03<sup>rd</sup> August, 2022 to the stock exchange, BSE Limited, where the debt securities of the Company are listed. A copy of the newspaper cutting is enclosed herewith.

Please take on your records.

**For Aragen Life Sciences Private Limited**

**Ramakrishna Kasturi**

Company Secretary & Compliance Officer



## Goyal may Meet Traders on Export Targets

Kirtika.Suneja  
@timesgroup.com

**New Delhi:** Commerce and industry minister Piyush Goyal is likely to meet export promotion councils on Friday to discuss the country's export performance, targets and various trade agreements India is currently negotiating. The meeting comes in the wake of India's exports dipping in July, the trade deficit touching a record high, and exporters raising concerns at the global slowdown impacting India's outbound shipments in the next two quarters.

"It is a broader meeting to discuss free trade agreements, new products and markets and the overall trade scenario," said an official, adding that the ministry takes inputs from the industry regularly. India's exports shrank by 0.76% on-year to \$35.24 billion in July after 16 months, but the sequential contraction was sharper at 12.18% from June.

## CAG Flags Road Build

Our Bureau

**New Delhi:** The Comptroller and Auditor General (CAG) of India has flagged undue benefit to road builders through post-tender amendments in agreements signed with the National Highway Authority of India (NHAI).

The auditor noted that NHAI granted deferment of premium amounting to Rs 9,296.25 crore for a period of 8 years to 14 years, for 20 projects (till October 2019). This deferment was on the basis of a scheme formulated by NHAI after it assessed a revenue loss of Rs 98,115 crores to the exchequer if the projects were terminated.

"The scheme was formulated on the basis of flawed presumptions," the CAG stated.

CAG said that the premium payable by the concessionai-

## ARAGEN LIFE SCIENCES PRIVATE LIMITED

(formerly known as GVK Biosciences Private Limited)

CIN: U74999TG2000PTC035826



Registered and Corporate Office: Plot 28A, IDA Nacharam, Hyderabad  
Telangana-500076, India

Tel: +91 40 6692 9999 F: +91 40 6692 9900

Email id: compliances@aragen.com, website: www.aragen.com

Extract of revised financial results for the quarter and year ended 31 March 2022 (₹ in million)


S. No.	Particulars	Standalone			Consolidated		
		Quarter ended	For the year ended		Quarter ended	For the year ended	
		31 March 2022	31 March 2022	31 March 2021	31 March 2022	31 March 2022	31 March 2021
		Unaudited	Audited	Audited	Unaudited	Audited	Audited
1	Total Income from operations	3,181.98	12,359.68	9,501.77	3,654.16	13,873.61	11,332.79
2	Net Profit / (Loss) for the period (before tax, Exceptional and/or Extraordinary Items)	664.86	2773.55	1992.16	650.50	2,673.66	2,169.02
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	664.86	2773.55	1992.16	650.50	2,673.66	2,169.02
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	516.46	2,109.78	1,476.21	500.15	1,974.63	1,642.77
5	Discontinued operations <sup>^</sup>						
	Profit before tax from discontinued operations	—	—	—	—	—	639.28
	Tax expense of discontinued operations	—	—	—	—	—	104.57
	Profit from discontinued operations after tax	—	—	—	—	—	534.71
6	Total Comprehensive Income for the period	467.12	2,120.18	1,809.00	440.84	1,968.75	2,503.04
7	Paid up Equity Share Capital	681.38	681.38	669.82	681.38	681.38	669.82
8	Reserves (excluding Revaluation Reserve)	9,748.52	9,748.52	7,633.17	9,640.54	9,640.54	8,414.32
9	Securities Premium Account	391.33	391.33	185.81	391.33	391.33	185.81
10	Net worth	10,429.90	10,429.90	8,302.99	10,321.92	10,321.92	9,084.14
11	Paid up Debt Capital/ Outstanding Debt	5,208.07	5,208.07	2,469.54	5,208.07	5,208.07	2,670.45
12	Outstanding Redeemable Preference Shares	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
13	Debt Equity Ratio*	0.50	0.50	0.30	0.50	0.50	0.29
14	Earnings Per Share (EPS) (Face value of ₹ 10 each fully paid) (for continuing and discontinued operations)*.						
	Basic EPS (Rs)	7.69	31.42	22.31	7.33	29.20	29.68
	Diluted EPS (Rs)	7.60	31.06	21.76	7.25	28.87	28.95
15	Capital Redemption Reserve	3.36	3.36	3.36	3.36	3.36	3.36
16	Debenture Redemption Reserve	200.00	200.00	—	200.00	200.00	—
17	Debt Service Coverage Ratio*	4.42	4.08	3.61	4.45	3.97	4.58
18	Interest Service Coverage Ratio*	7.72	13.19	12.65	7.46	12.37	12.96

\*Quarter ended ratios are not annualised.

\*EPS not annualised for the quarters.

^ Pursuant to the Corporate Scheme of Arrangement, approved by the NCLT.

**Growth.**  
**Rising market share.**  
**Capacity expansion.**  
**New-age product led innovation.**



## EXTRACT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2022

Sr. No.	Particulars	Standalone	
		Quarter Ended	Year Ended
		30.06.2022 (Unaudited)	31.03.2022 (Audited)
1.	Total Income from Operations	39,575.07	1,44,175.00
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items)	5,296.13	20,901.00
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary items)	5,296.13	20,327.00
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary items)	3,963.22	14,935.00
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	3,940.77	14,825.00
6.	Equity Share Capital (Face value of ₹ 5/- each)	650.29	650.00
7.	Other Equity (Excluding revaluation reserve) as shown in the Audited Balance Sheet of the previous year		99,924.00
8.	Earnings per equity share (of ₹ 5/- each) (EPS for the quarter not annualised):		
	(1) Basic (Rs.)	30.47	114.00
	(2) Diluted (Rs.)	30.47	114.00

### Notes:

- The above is an Extract of the detailed format of results for quarter ended on 30<sup>th</sup> June 2022 (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly/annual financial results are available on the website of the Company's website ([www.cera-india.com](http://www.cera-india.com)).
- Figures of the previous periods have been regrouped/ reclassified / restated wherever necessary.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors.

Date: 04.08.2022

Place: Ahmedabad

## Cera Sanitaryware Limited

Registered Office & Works: 9, GIDC Industrial Estate, Kadi - 382 715  
CIN: L26910GJ1998PLC034400 Tele: (02764) 242329, 243000. E-mail: [info@cera-india.com](mailto:info@cera-india.com)

### Notes:

- The above is an extract of the detailed format of quarterly/annual financial results filed with the stock exchange under Regulation 52 of the Listing Regulations as the company's debt securities are listed. The full format of the quarterly/annual financial results are available on the websites of the stock exchange- BSE Limited at [www.bseindia.com](http://www.bseindia.com) and the company at [www.aragen.com](http://www.aragen.com).
- For the other line items referred to in Regulation 52(4) of the LODR Regulations, pertinent disclosures have been made to the stock exchange, BSE Limited, and can be accessed at [www.bseindia.com](http://www.bseindia.com).
- The above revised financial results for the quarter and year ended 31 March 2022 ("the statements") which are published in accordance with Regulation 52 of the LODR Regulations, have been reviewed and recommended by the Audit Committee and approved by Board of Directors at its meeting held on 03 August 2022. The earlier financial results of the Company for the year ended 31 March 2022 were first approved by the Board of Directors on 26 May 2022 and are being revised pursuant to giving effect to the Composite Scheme of Arrangement.
- Figures for the quarter ended 31 March 2022 represents the balancing figure between the audited figures in respect of the full financial year and the unaudited year to date figures up to the third quarter of the current financial year.
- The Company started publishing quarterly results from quarter ended 31 March 2022 and hence quarterly figures for the quarter ended 31 March 2021 have not been given basis exemption allowed by SEBI vide their circular dated 05 October 2021.

## Extract of standalone financial results for the quarter ended 30 June 2022 (₹ in million)

S. No.	Particulars	Quarter ended		Year ended
		30 June 2022	30 June 2021	31 March 2022
		Unaudited	Unaudited	Audited
1	Total Income from operations	3,782.81	2,565.45	12,359.68
2	Net Profit / (Loss) for the period (before tax, Exceptional and/or Extraordinary items)	713.83	498.42	2,773.55
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	713.83	498.42	2,773.55
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	536.50	367.83	2,109.78
5	Total Comprehensive Income for the period	238.76	321.95	2,120.18
6	Paid up Equity Share Capital	681.38	678.41	681.38
7	Reserves (excluding Revaluation Reserve)	9,989.93	7,869.17	9,748.52
8	Securities Premium Account	391.33	367.48	391.33
9	Net worth	10,671.31	8,547.58	10,429.90
10	Paid up Debt Capital/ Outstanding Debt	5,091.86	2,352.97	5,208.07
11	Outstanding Redeemable Preference Shares	N.A.	N.A.	N.A.
12	Debt Equity Ratio*	0.48	0.28	0.50
13	Earnings Per Share (EPS) (Face value of ₹ 10 each fully paid)*			
	Basic EPS (Rs)	7.97	5.52	31.42
	Diluted EPS (Rs)	7.87	5.44	31.06
14	Capital Redemption Reserve	3.36	3.36	3.36
15	Debenture Redemption Reserve	200.00	N.A.	200.00
16	Debt Service Coverage Ratio*	4.22	4.12	4.08
17	Interest Service Coverage Ratio*	7.93	12.26	13.19

\*Quarter ended ratios are not annualised.

\*EPS not annualised for the quarters.

### Notes:

- The above is an extract of the detailed format of quarterly/annual financial results filed with the stock exchange under Regulation 52 of the Listing Regulations as the company's debt securities are listed. The full format of the quarterly/annual financial results are available on the websites of the stock exchange- BSE Limited at [www.bseindia.com](http://www.bseindia.com) and the company at [www.aragen.com](http://www.aragen.com).
- For the other line items referred to in Regulation 52(4) of the LODR Regulations, pertinent disclosures have been made to the stock exchange, BSE Limited, and can be accessed at [www.bseindia.com](http://www.bseindia.com).
- The above standalone financial results for the quarter ended 30 June 2022 ("the statements") which are published in accordance with Regulation 52 of the LODR Regulations, have been reviewed and recommended by the Audit Committee at its meeting held on 03 August 2022. The Board of Directors at its meeting held on 03 August 2022 have approved the above results and taken them on record.
- The Company has started publishing quarterly results from quarter ended 31 March 2022 and hence quarterly figures for the quarter ended 30 June 2021 were neither reviewed nor subjected to audit, however, the management has exercised necessary due diligence to ensure that the financial results for this period provide a true and fair view of the Company's affairs.

For Aragen Life Sciences Private Limited  
Sd/-

Manmahesh Kantipudi  
Director & CEO  
DIN: 05241166

Date: 3<sup>rd</sup> August, 2022

Place: Hyderabad